Michael W. Boyer, MD
Email: michael.boyer@hsc.utah.edu
Education:
1983 – 1987 M.D., Indiana University, Bloomington, Indiana
1979 – 1982 B.S., Indiana University, Bloomington, Indiana
Training:
1994 – 1995 Research Fellow in BMT, University of Minnesota, Minneapolis, Minnesota
1991 – 1993 Fellow in Pediatric Hematology/Oncology/BMT, University of Minnesota, Minneapolis, Minnesota
1987 – 1990 Intern/Resident in Pediatrics, University of Minnesota, Minneapolis, Minnesota
Research Interests:
Adoptive T cell therapy of cancer
Non-myeloablative allogeneic hematopoietic cell transplantation for myelofibrosis
Graft-vs-leukemia
Graft-vs-host disease treatment
Recent Publications
- Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura RA. (2006). Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther, 5(3), 693-703.
- Adamkiewicz TV, Boyer MW, Bray R, Haight A, Yeager AM. (2006). Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. J Pediatr Hematol Oncol, 28(1), 29-32.
- Adamkiewicz TV, Mehta PS, Boyer MW, Kedar A, Olson TA, Olson E, Chiang KY, Maurer D, Mogul MJ, Wingard JR, Yeager AM. (2004). Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant, 34(5), 405-11.
- Boyer MW, Gross TG, Loechelt B, Leemhuis T, Filipovich A, Harris RE. (2003). Low risk of graft-versus-host disease with transplantation of CD34 selected peripheral blood progenitor cells from alternative donors for Fanconi anemia. J Pediatr Hematol Oncol, 25(11), 890-5.
